Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Bio-Rad Laboratories (BIO-B) Short-Term Debt issuances (2012 - 2017)

Bio-Rad Laboratories (BIO-B) reported Short-Term Debt issuances of -$36000.0 for Q1 2017, down 197.3% on a QoQ basis from $37000.0 in Q4 2016.

Bio-Rad Laboratories (BIO-B) has 6 years of Short-Term Debt issuances data on file, last reported at -$36000.0 in Q1 2017.

  • Quarterly Short-Term Debt issuances changed N/A year-over-year to -$36000.0 in Q1 2017, while the trailing twelve-month figure through Dec 2017 was -$36000.0 (down 197.3% YoY) and the FY2017 annual result came in at -$36000.0, down 197.3% from the prior year.
  • Short-Term Debt issuances declined to -$36000.0 in Q1 2017 per BIO-B's latest filing, from $37000.0 in the prior quarter.
  • Across five years, Short-Term Debt issuances topped out at $74000.0 in Q3 2015 and bottomed at -$1.2 million in Q4 2014.
  • The 5-year median for Short-Term Debt issuances is -$19000.0 (2013), against an average of -$137363.6.
  • The widest annual swing landed in 2013, when Short-Term Debt issuances surged 200.0%; it then slumped 1915.15% in 2014.
  • Tracing BIO-B's Short-Term Debt issuances over 5 years: stood at $66000.0 in 2013, then tumbled by 1915.15% to -$1.2 million in 2014, then jumped by 93.82% to -$74000.0 in 2015, then soared by 150.0% to $37000.0 in 2016, then plunged by 197.3% to -$36000.0 in 2017.
  • Per Business Quant, the three latest BIO-B Short-Term Debt issuances figures stand at -$36000.0 (Q1 2017), $37000.0 (Q4 2016), and -$74000.0 (Q4 2015).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Short-Term Debt issuances (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 31.00 Mn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -1.23 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -1.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 37.80 Mn
10 Bio-Rad Laboratories - - 309.40 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2017 -36,000.00
Mar 31, 2017 -36,000.00
Dec 31, 2016 37,000.00
Dec 31, 2016 37,000.00
Dec 31, 2015 -74,000.00
Dec 31, 2015 -74,000.00
Sep 30, 2015 74,000.00
Sep 30, 2015 74,000.00
Dec 31, 2014 -1.20 Mn
Dec 31, 2014 -1.20 Mn
Sep 30, 2014 -300,000.00
Sep 30, 2014 -300,000.00
Jun 30, 2014 -12,000.00
Jun 30, 2014 -12,000.00
Mar 31, 2014 -50,000.00
Mar 31, 2014 -50,000.00
Dec 31, 2013 66,000.00
Dec 31, 2013 66,000.00
Jun 30, 2013 1,000.00
Jun 30, 2013 1,000.00
Mar 31, 2013 -19,000.00
Mar 31, 2013 -19,000.00
Dec 31, 2012 22,000.00
Dec 31, 2012 22,000.00